...678910...203040...


Peripheral Nerve Repair Devices Market Research Report by Device, by Application, by End User – Global Forecast to 2025 – Cumulative Impact of…

New York, July 29, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Peripheral Nerve Repair Devices Market Research Report by Device, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05941595/?utm_source=GNW

The Global Peripheral Nerve Repair Devices Market is expected to grow from USD 5,396.43 Million in 2019 to USD 11,283.48 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 13.08%.

Market Segmentation & Coverage:This research report categorizes the Peripheral Nerve Repair Devices to forecast the revenues and analyze the trends in each of the following sub-markets:

"The Neurostimulation & Neuromodulation Device is projected to witness the highest growth during the forecast period"

Based on Device, the Peripheral Nerve Repair Devices Market studied across Biomaterial and Neurostimulation & Neuromodulation Device. The Biomaterial further studied across Nerve Conduit, Nerve Connector, Nerve Protector, and Nerve Wrap. The Neurostimulation & Neuromodulation Device further studied across External Neurostimulation Device and Internal Neurostimulation Device. The Biomaterial commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Neurostimulation & Neuromodulation Device is expected to grow at the fastest CAGR during the forecast period.

"The Nerve Grafting is projected to witness the highest growth during the forecast period"

Based on Application, the Peripheral Nerve Repair Devices Market studied across Direct Nerve Repair/Neurorrhaphy, Nerve Grafting, Neurostimulation & Neuromodulation Surgery, and Stem Cell Therapy. The Direct Nerve Repair/Neurorrhaphy further studied across Epineural Repair, Group Fascicular Repair, and Perineural Repair. The Nerve Grafting further studied across Allograft, Autograft, and Xenograft. The Stem Cell Therapy commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Nerve Grafting is expected to grow at the fastest CAGR during the forecast period.

"The Ambulatory Surgery Center is projected to witness the highest growth during the forecast period"

Based on End User, the Peripheral Nerve Repair Devices Market studied across Ambulatory Surgery Center and Hospital & Clinic. The Hospital & Clinic commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Ambulatory Surgery Center is expected to grow at the fastest CAGR during the forecast period.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

Based on Geography, the Peripheral Nerve Repair Devices Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Peripheral Nerve Repair Devices Market in 2019. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Peripheral Nerve Repair Devices Market including Axogen Inc., Baxter International, Boston Scientific Incorporation, Cyberonics Inc., GlaxoSmithKline Pharmaceuticals Ltd., Integra LifeSciences Corporation, Medovent GmbH, Medtronic PLC, NeuroMetrix, Inc., Orthomed S.A.S., Polyganics B.V., Renerva, LLC,, St. Jude Medical, Stryker Corporation,, Synovis Micro Companies Alliance, Inc., and Toyobo Co., Ltd..

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Peripheral Nerve Repair Devices Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Peripheral Nerve Repair Devices Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Peripheral Nerve Repair Devices Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Peripheral Nerve Repair Devices Market?4. What is the competitive strategic window for opportunities in the Global Peripheral Nerve Repair Devices Market?5. What are the technology trends and regulatory frameworks in the Global Peripheral Nerve Repair Devices Market?6. What are the modes and strategic moves considered suitable for entering the Global Peripheral Nerve Repair Devices Market?Read the full report: https://www.reportlinker.com/p05941595/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Excerpt from:

Peripheral Nerve Repair Devices Market Research Report by Device, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of...

Family need to raise 120K by September for lifesaving treatment for 11-year-old – Cheshire Live

The family of a brave 11-year-old Wistaston boy needs to raise 120,000 by September so he can have lifesaving treatment in Asia to stop a rare form of bone cancer returning.

Georgy Capener was diagnosed with the highly malignant Ewings Sarcoma after a fall in a friends back garden on Easter Sunday in 2018.

Since then the plucky Wistaston Church Lane pupil has undergone numerous rounds of high dose aggressive chemotherapy and radiotherapy.

As a result of the treatment he lost his right arm which has been replaced a titanium prosthesis.

Georgy went into remission in March of last year and life returned to a semblance of normality for the Crewe boy, his mum Helen, dad Richard, and sisters Ellie, 18, and Chloe, 13.

But in April this year the family were dealt another devastating blow when they learned the cancer had returned - this time in Georgys left sinus, just under his eye socket and in the back of his nose.

Helen told CheshireLive: Everything had been going really well and then there was the impact of the coronavirus pandemic so one scan [to check Georgy] was moved further on but we never got to it because he started having really painful headaches. I knew something wasnt right.

Georgys parents were told that, because of the location of the tumour, there was a chance he could lose his eyesight or suffer a stroke during the biopsy he needed.

Helen told how, at first, she didnt want him to have the biopsy, but she knew he had to.

We didnt know if he was going to come out with his eyesight or have a stroke but he came through it, she said. Hes so brave, hes been so brave throughout.

Georgy, who is a passionate Liverpool fan, is now undergoing chemotherapy and radiotherapy again.

The tumour cannot be removed surgically because of its location.

But the vital stem cell therapy which is essential to ensure he can live a normal, healthy life and prevent the cancer returning at a later stage costs 130,000 and is not available for Georgy on the NHS.

Helen said: After lengthy discussions with a stem cell transplant hospital in a top medical treatment centre in Thailand, we are thrilled that they are willing to accept Georgy.

The transplant will involve removing the faulty mother cell and harvesting new purified cells from a donated umbilical cord into his body to stop the cancer from returning. These procedures have very high success rates.

Georgy is due to finish his sixth and final round of chemotherapy at the beginning of September.

For the stem cell treatment to be successful the procedure would have to start immediately after that to ensure the cancer doesnt return straight away.

The family has set up a JustGiving appeal to raise the funds needed to save their little boys life. They need to raise 120,000 by the beginning of September.

Helen said: We set it up in the hope that we can raise some of this amount to help save our sons life. It is our only realistic option and, for the first time in a long time, we can be positive and see some sort of future.

If you can help please donate by visiting JustGiving here.

Read more:

Family need to raise 120K by September for lifesaving treatment for 11-year-old - Cheshire Live

Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine and the Ontario Institute for Regenerative Medicine Partner to Boost…

TORONTO & MONTREAL--(BUSINESS WIRE)--Regenerative medicine (RM) has the potential to transform healthcare by developing curative therapies for diseases such as heart failure or vision loss. By repairing damaged tissues and organs, this will not only improve patients lives but create economic impact in a market forecasted to reach $5.6B USD by 2025.

Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine (OIRM) and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine (C3i).

Each organization will leverage their unique resources and expertise to help Canadian research teams overcome common but significant hurdles in the RM translational process, from clinical trials through to therapeutic application.

C3i is a funded Centre of Excellence in Commercialization and Research of the federal governments Networks of Centres of Excellence program. It accelerates the development of cancer immunotherapies and cellular-based therapies by providing one-stop-shop services in the chain of product development through to commercialization, as well as supporting Canadian-based companies working in this space.

OIRM is a comprehensive clinical translation ecosystem in Ontario focused on translating promising RM research from the lab to the clinic. Unfortunately, OIRMs core provincial funding was not renewed, compromising multiple world-class translational research programs at pivotal points in clinical development.

Our partnership with C3i is truly a win-win for both organizations, for RM research in Ontario and Canada, and for the health of Canadians, says Dr. Duncan Stewart, President and Scientific Director, OIRM. With C3is deep commercialization resources and manufacturing expertise, OIRM will be able to shift our translational pipeline into high gear. In turn, OIRM will help C3i achieve lateral growth in the RM field on par with their impact to date in the field of cancer immunotherapy.

The CEO of C3i, Mr. Benoit Deschamps, says: We believe that the C3i-OIRM partnership truly expands the one-stop-shop model in supporting cell and gene therapies for Canadian technologies.

In addition to supporting commercialization and manufacturing activities, OIRM and C3i will launch a joint Industry and Investor Program that will include pitch days technology scouting calls tailored to the interested organization as well as opportunities to work alongside researchers to develop strategic solutions needed to advance technologies through the pipeline.

The C3i-OIRM partnership will be guided via a joint steering committee. The OIRM administrative centre and a satellite office for C3i will share space in Torontos MaRS Discovery District.

As part of its Canadian mandate, C3i is excited to expand the Ontario-Quebec corridor and support innovation, ensuring that Canadian technology in cell and gene therapy space can flourish and remain accessible to Canadians, said Mr. Deschamps.

Go here to see the original:

Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine and the Ontario Institute for Regenerative Medicine Partner to Boost...

Literature Review of Surgical Treatment in Idiopathic Full-Thickness M | OPTH – Dove Medical Press

Mantapond Ittarat,1,2 Thanapong Somkijrungroj,2,3 Sunee Chansangpetch,2,4 Pear Pongsachareonnont2,3

1Surin Hospital and Surin Medical Education Center, Department of Ophthalmology, Suranaree University of Technology, Surin, Thailand; 2Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 3Vitreoretinal Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 4Glaucoma Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Correspondence: Pear Pongsachareonnont Department of Ophthalmology, Faculty of Medicine 1873 Rama IV Road, Patumwan, Bangkok 10330, ThailandTel +66-2256-4142Fax +66-2-252-8290Email pear.p@chulahospital.org

Purpose: To summarize current surgical techniques for treating primary macular holes (MHs).Methods: We reviewed publications detailing surgical approaches to primary MHs, briefly described their protocols, and outlined their results.Results: Currently, the technique for primary MH repair is pars plana vitrectomy, removing the posterior cortical vitreous, stripping the epiretinal membranes, and ending with intraocular gas tamponade. The evident benefit of peeling off the internal limiting membrane (ILM) was clearly shown for MHs at stages 2 to 4 by achieving an anatomical closure rate of > 90%, even in large MH up to 650 m. Newer MH surgical techniques include modification of ILM flap techniques, placing an autologous scaffolding of tissue within the hole, and cell therapy has shown to increase the closure rate of large and chronic macular holes, resulting in modest functional improvement in complicated MHs.Conclusion: Since the turn of the century, the success rate of modern macular surgery has increased, even for large and chronic MHs. There seems to be no limit to novel concepts in MH surgery, which range from anatomical closure to those proposing natural restoration of visual function via stem cell therapy.

Keywords: macular hole, macular hole surgery, stem cell therapy, internal limiting membrane peeling

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the rest here:

Literature Review of Surgical Treatment in Idiopathic Full-Thickness M | OPTH - Dove Medical Press

Five developments in oncology targets – Drug Target Review

Drug Target Review explores some of the newest oncologic drug targets, including those for glioblastoma, lung cancer and breast cancer.

According to new research published inDevelopmental Cell, the PRC1 protein is an essential component in cell division. Acting as a viscous glue, the protein creates resistance as cells pull chromatids to either end of the single dividing cell.

The team explains that this process controls the speed that DNA is separated into daughter cells, suggesting that the over-abundance of PRC1 characteristic observed in many cancer types (including prostate, ovarian and breast cancers) may be causing the cells to divide unevenly, resulting in chromosomal abnormalities and driving cancer growth and mutation.

PRC1 produces a viscous frictional force, a drag that increases with speed, said Scott Forth, an Assistant Professor of Biological Sciences and member of the Center for Biotechnology and Interdisciplinary Studies at Rensselaer Polytechnic Institute in the US. The friction it produces is similar to that of water if you try to move your hand through water slowly, you move easily, but if you push your hand fast, the water pushes back hard.

The team explained that correct cellular division relies on physical forces produced by motor proteins and microtubules, essentially ripping pairs of chromatids apart so a single cell of the cellular DNA ends up in each daughter cell. The mitotic spindle is an element of cellular machinery that uses mechanical forces push, pull and resistance to complete the task.

We think the force PRC1 produces is integrating and dampening out cellular motions as the DNA is separated so that ultimately, you get the correct rate of chromosome segregation, Forth said. However, if this process goes awry due to too much or too little PRC1, it can cause uncontrollable cancer growth.

Researchers have found that expansion stress can drive breast tumours to become highly aggressive in their growth, invasion and metastasis.

Expansion stress is a condition often seen in solid cancer tumours when, as they grow, biomechanical forces in the tumour microenvironment cause compression within the tumour, tension at its periphery and altered interstitial fluid flow.

The interdisciplinary team from the University of Alabama at Birmingham (UAB), US, also suggested that the biomechanical forces may modulate the immune response through cancer cell-immune cell crosstalk.

To explore how these biomechanical forces may be impacting breast cancer growth, the researchers created a tissue-engineered, three-dimensional (3D) breast cancer mimetic system that recapitulates the in vivo growth of breast cancer cells. It includes tumour-associated fibroblasts, endothelial cells and immune cells, within a physiologically relevant extracellular matrix.

According to the team, the biomechanical forces significantly altered the proteome of breast cancer cells and enhanced exosome production. These tumour cell-secreted exosomes are one of the intercellular mediators of signalling in the tumour microenvironment and are now considered key regulators of tumour progression.

In the study, the exosomes promoted aggressive tumour cell growth, induced immune suppression and altered immune cell polarisation in the tumour microenvironment. Furthermore, the researchers recently engineered an oscillatory compression device for real-time application of biomechanical force on orthotopic mammary tumours in mice, which allowed them to observe exosome-mediated immunosuppression and aggressive tumour growth.

The researchers concluded that their study suggests that exposure to mechanical strain promotes invasive and pro-tumourigenic phenotypes of breast cancer cells. They also added that mechanical strain also impacted the growth and proliferation of cancer cells, altered exosome production and induced immunosuppression in the tumour microenvironment.

The paper was published in Laboratory Investigation.

Researchers studying lung cancers revealed that the cancers observed in non-smokers are distinctly different to those in smokers, with different genetic underpinnings dependent on age, and lifestyle. They suggest that some patient populations may respond to targeted treatments better than others.

The study, conducted in Taiwan, was co-led by scientists at The Institute of Cancer Research.

According to the scientists, around 10-15 percent of lung cancers in the UK occur in people who have never smoked, but in East Asia this proportion is much higher, especially among women.

The study, published in Cell, details the analyses of tumour samples from 103 lung cancer patients from Taiwan, the majority of which were non-smokers. The researchers conducted a detailed analysis of genetic changes, gene activation, protein activity and cellular switches in lung cancer to develop a comprehensive picture of the biology of lung cancers in non-smokers.

Looking at the genetics and the related proteins produced by cancer cells in the tumour samples, the team found that some early-stage lung tumours in non-smokers were biologically similar to more advanced disease in smokers.

Tumours in females typically had a defect in the epidermal growth factor receptor (EGFR) gene, whereas in men the most common mutations were in the KRAS (Ki-ras2 Kirsten rat sarcoma viral oncogene homologue) and adenomatous polyposis coli (APC) genes. The team suggested this could cause the two sexes to respond differently to treatments.

The study also identified a pattern of genetic changes involving the APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like)gene family in 75 percent of tumours in female patients under the age of 60 and 100 percent of with no mutation in the EGFR gene.

APOBEC proteins play an important role in the function of the immune system but can be hijacked by cancers to speed up their evolution, which can expedite the development of drug resistance. According to the team, patients without EGFR defects tend to respond better to immunotherapy and suggest that testing for APOBEC could help identify women more likely to respond.

Finally, the team identified 65 proteins that were overactive in the tumours that could be targeted by existing drug candidates.

While the new study included patients treated in Taiwan, the researchers believe that many of their findings could be applicable to UK patients. They will be validating their findings in larger studies and beyond Asia.

Dr Jyoti Choudhary, Team Leader in Functional Proteomics at ICR, UK, said: We carried out the most comprehensive study ever conducted into the biology of lung cancers in an East-Asian population with a high proportion of non-smokers and found that their disease is molecularly diverse and distinct from what we classically see in smokers.

We observed distinct patterns of genetic faults in non-smokers and between women and men, which suggest that a woman who has never smoked, for example, is likely to respond differently to treatment than a male smoker.

Dr Emily Armstrong, Research Information Manager at Cancer Research UK, said: In order to beat cancer, we need to understand all the ways it can develop Understanding the difference between lung cancers in smokers and non-smokers could be vital for providing patients with the most appropriate treatment.

Scientists have identified a population of cells within glioblastomas from which all other cancerous cells within the tumour arise. They suggested that targeting these glioblastoma stem cells (GSCs) could be a potent future treatment option.

Tumour heterogeneity, or the genetic variation of tumour cells, is one reason why brain cancers can be resistant to treatments. After a treatment, resistant cells remain and subsequently repopulate the tumour.

In a new study, researchers identified a cancer cell hierarchy, indicating that each cell originates from a single cancer cell type, coined glioblastoma stem cells by the team. They suggested that targeting these cells with drug interventions could therefore slow cancer growth.

The team began by sequencing the RNA from 55,000 glioblastoma cells and 20,000 normal brain cells. They identified five main cancer cell types within each tumour and found that these are similar to cell types found within the human brain.

One cell type described was a progenitor GSC, a cell type from which all other glioblastoma cells would develop. They further showed that there was a cellular hierarchical organisation to the cancer that originates from progenitor GSCs.

According to the team, GSCs divided at a faster rate than the mature cancer cells. In fact, they made up most of the dividing cells within the tumour, despite making up a relatively small proportion of the cells within the whole tumour. These rapidly dividing cells are the earliest detectable cancer cells in the hierarchy, suggesting they are a promising target for therapy.

The researchers identified that molecular vulnerabilities of the progenitor GSCs and targeted them in experiments. They found that progenitor GSC survival and proliferation decreased as a result of these interventions and that in pre-clinical disease models, this reduced tumour growth and increased survival of the animals.

Our work has gone a long way to resolve the complexity of glioblastoma heterogeneity and provides a new framework to reconsider the nature of glioblastoma, explained research leader, Dr Kevin Petrecca, a neurosurgeon and brain cancer researcher at The Neuro (Montreal Neurological Institute and Hospital) of McGill University, part of the McGill University Health Centre in Canada. As part of this work, our study also shows, in contrast to decades long dogma, that glioblastoma stem cells are the most rapidly dividing cancer cells in the tumour, and we identified new ways to target these cells. There is still much work to be done. Understanding how these cancer cells interact with the cancer microenvironment is not well understood in this disease, but this study serves as a good starting point to begin to understand how glioblastoma originates and evolves prior to treatments.

This study was published in Nature Communications.

Scientists have identified AVIL as an oncogene responsible for glioblastoma, the deadliest brain tumour. According to the researchers, the discovery offers a promising new treatment target for this cancer, as this gene is vital to the survival of glioblastoma cancer cells.

Glioblastoma is one of the most deadly cancers. Unfortunately, there is no effective treatment option for the disease, said researcher Dr Hui Li, of the University of Virginia School of Medicine and the UVA Cancer Centers Department of Pathology, both US. The novel oncogene we discovered promises to be an Achilles heel of glioblastoma, with its specific targeting potentially an effective approach for the treatment of the disease.

In this study, Li and colleagues identified AVIL, a gene that is typically involved in cells maintaining their size and shape, as an oncogene that can cause cancer cells to form and spread.

In their experiments, blocking AVIL destroyed glioblastoma cells within mice, but had no effect on healthy tissue. The team concluded that therapies targeting this gene are likely to be highly effective and selective.

AVIL is overexpressed in 100 percent of glioblastoma cells and clinical samples, and is expressed at even higher levels in so-called glioblastoma stem cells, but hardly expressed in normal cells and tissues, said Li. Silencing the gene wiped out glioblastoma cells in culture and prevented animal xenografts, while having no effect on normal control cells. Clinically, high AVIL expression correlates with worse patient outcomes. These findings and classic transformation assays proved AVIL being a bona fide oncogene.

The researchers said that the AVIL gene plays a critical role in glioblastoma development and survival. Li added that the strategy they used to identify this oncogene, studying a structural variant identified in a paediatric cancer, could be used to identify other genes driving other adult cancers.

The paper was published in Nature Communications.

Link:

Five developments in oncology targets - Drug Target Review

Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global stem cell therapy market size and it is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Frequently Asked Questions:

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Gilead Sciences Inc., Holostem Terapie Avanzate Srl, Lineage Cell Therapeutics Inc., Lonza Group Ltd., Novartis AG, Nuvasive Inc., Organogenesis Inc., Osiris Therapeutics Inc., RTI Surgical Holdings Inc., and Vericel Corp. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

An increase in awareness of stem cell therapy has been instrumental in driving the growth of the market.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Stem Cell Therapy Market 2020-2024: Segmentation

Stem Cell Therapy Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43432

Stem Cell Therapy Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The stem cell therapy market report covers the following areas:

This study identifies the limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Stem Cell Therapy Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer Landscape

Geographic Landscape

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Visit link:

Global Stem Cell Therapy Market Analysis Highlights the Impact of COVID-19 2020-2024| Increase in Awareness of Stem Cell Therapy to Boost Market...

American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public – PRNewswire

MIAMI, July 29, 2020 /PRNewswire/ --An FDA Safety Panel discussion will be held virtually by the American Academy of Stem Cell Physicians (AASCP) Aug.1-3, 2020, with guest speakerFDA Director Dr. Peter Marks. This is a highly anticipated session which will discuss the growing safety concerns of the industry.

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought-after Safety StandardsPanel session will be hosted VIRTUALLY by AASCP on Aug. 1-3. 2020; guest of honor isDr. Peter Marks, FDA Director of CBER. The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open and free to the public, covering the growing safety concerns of the industry.

The Safetypanel discussion will discuss advancements in development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. The Safety Panel discussion willbringtogether experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory and patient decision-making.

According to AASCP, if physicians are using biologics in their practice, whether they are using SVF, PRP, bone marrow, UCB, amniotic products, exosomes, xenograftsor peptides, there are key considerations to take into account to achieve the best safety for their patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory they work with. AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for their patients. Sales agents typically do not have a medical or scientific background.

The President for the AASCP, Dr. Martin Dayton,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy fromSVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever-growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Aug. 1-3, 2020, is to help get rid of the bad actors that are damaging the field for everyone."

The importance of this virtual conference coincides with the ever-emerging growthof the globalregenerative medicine marketwhich is expected to reachUSD 79.8 billionby 2024, at aCAGR of 20.5%from 2018 to 2024. Factors driving the growth of the market areincreasing prevalence of degenerative and chronic diseases, technological advancements in nanotechnology, bioengineering and stem cell therapy, and increasing geriatric population across the globe.TheAASCP virtual meeting is set for Aug. 1, 2020.List of speakers is available at http://www.aascp.net.

Due to COVID-19, the meeting will take place virtually.Thisis an effective way to ensure that everyone that wishes to participate, but cannot travel, can. Students, educators and physicians will not have to miss out on all the important topics that AASCP has on the pipeline.

Virtual Workshop Lecturers will virtually demonstrate their techniques live via their professional locations. These virtualinteractive workshops will feature small participant-to-instructor ratios with a customized curriculum focusing on developing hands-on skills. Each technique will be taught by experts in the field, using didactic sessions with dynamic multimedia presentations, live demonstrations and scanning on live models, as well as phantoms.

AASCP spokesmanDr. A.J.Farshchianexplains, "We will duplicate everything we did in our past meetings such as offer CME credits, have lectures, workshops, discuss FDA safety standards, have board examinations and a virtual graduation ceremony. AASCP is offering this virtual meeting so that nobody misses out on the education."

To join the free session via Zoom, please click on the link below at 11a.m. this Saturday.

Join Zoom Meeting:https://aascp.zoom.us/j/4150937630

Meeting ID: 415 093 7630

The American Academy of Stem Cell Physicians (AASCP) is a non-profit organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. Secondarily, the AASCPaims to serve as an educational resource for physicians, scientists, and the public in diseases that can be caused by physiological dysfunction that isameliorable to medical treatment.

For further information, please contact MarieBarbaat AASCP at 305-891-4686or visit us at http://www.aascp.net.

Related Images

virtual-conference-aug-1-3-2020.jpeg Virtual Conference Aug. 1-3, 2020

aascp.png AASCP

Related Links

Guest Speaker Dr. Peter Marks, FDA Director

AASCP zoom meeting

SOURCE American Academy of Stem Cell Physicians

View post:

American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public - PRNewswire

‘Self-eating’ stem cell process may be the key to new regenerative therapies – Penn Today

The self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs,Penn Medicineresearchers show in a new study published online inScience.

Human bodies contain more than 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency. Researchers have known that the cells metabolism plays a role in this process; however, it wasnt clear exactly how the cells internal wiring works to keep that state and ultimately decide stem cell fate.

The new preclinical study, for the first time, shows how the stem cells keeps CMA at low levels to promote that self-renewal, and when the stem cell is ready, it switches that suppression off to enhance CMA, among other activities, and differentiate into specialized cells.

Its an intriguing discovery in the field of stem cell biology and for researchers looking to develop therapies for tissue or organ regeneration, says senior authorXiaolu Yang, a professor of cancer biology at the Abramson Family Cancer Research Institute in the Perelman School of Medicine. We reveal two novel ways to potentially manipulate the self-renewal and differentiation of stem cells: CMA and a metabolite, known as alpha-ketoglutarate, that is regulated by CMA. Rationally intervening or guiding these functions could be a powerful way to increase the efficiency of regenerative medicine approaches.

This story is by Melissa Moody. Read more at Penn Medicine News.

View original post here:

'Self-eating' stem cell process may be the key to new regenerative therapies - Penn Today

Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy – Press Release – Digital Journal

Johnny The Healer aka Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy. This is our newest addition to an already very powerful treatment method. Offering the most innovative holistic natural approach to healing the mind the body to soul.

Johnny Tabaie aka Johnny The Healer created The Holistic Sanctuary 10 years ago, he has taken by storm the holistic health movement by creating and pioneering this new paradigm of healing.

Treatments like Massage therapy, Reiki sessions, Kundalini Yoga, HBOT hyperbaric oxygen therapy chamber sessions, daily iv drips NAD+, Amino drips, O-Zone infusion therapy, Ayahuasca ceremonies, Ibogaine treatment, DMT sessions, Stem Cell treatment, holistic dentistry and much more.

The unique and carefully weaved holistic modalities create the most effective and innovative therapy protocols ever created to date. With 80% success rate, patients are not prescribed addictive or toxic medications, or undergo countless hours of talk therapy group therapy and psychobabble instead they are they receive 150 hours of holistic one on one in a four-week inpatient program.

Patients who suffer from depression, PTSD, anxiety, drug addiction, alcohol addiction, medication dependency all enroll to experience this life changing healing method.

The five-star reviews all over the Internet showcases to success, effectiveness and healing potential of Johnny Tabaies healing center.

Media ContactCompany Name: Johnny The HealerContact Person: Johnny TabaieEmail: Send EmailPhone: +1-310-601-7805City: Los AngelesState: CACountry: United StatesWebsite: http://www.johnnythehealer.com/

See the article here:

Johnny Tabaie is proud to announce the most powerful Stem Cell Therapy - Press Release - Digital Journal

Paralyzed man walks after 11 years with the help of Plexus Neuro and Stem Cell Research Centre, Bengaluru – PR Newswire India

Anand met with an unfortunate road accident and suffered spinal cord injury. He was suddenly propelled from the world of the able-bodied into the world of the disabled. He was paralyzed from below the neck and couldn't even wipe his tears, which emphasized his helplessness. Finally, Plexus entered Anand's life as a glimmer of hope and Anand rehabilitation was seen as a triumphant fight where the treating team played an imperative role.

Dr Naeem Sadiq, Consultant Neurologist, Founder & Director of Plexus Neuro and Stem Cell Research Centre said, "In Anand's 11 years struggle, I saw a possibility of recovery and his father entrusted his hopes and desires on Plexus and then his journey towards recovery started. At Plexus, he was subjected to a customized treatment approach, which was planned after carrying out a critical evaluation of his strengths and weaknesses."

He further said, "A group of Rehabilitation professionals focused on every aspect of his recovery starting from his poor posture to the use of his hands and walking."

His treatment comprised of stem cell therapy & comprehensive rehabilitation program which focused on improving his strength, sensation, daily activities and bowel and bladder control. After an arduous excursion of 120 days, Anand was able to use his hands to hold a spoon and eat, write, wear his clothes and hold a walker to walk independently. His trunk became steady and regained its balance, his legs started bearing weight and he even started feeling his bowel and bladder sensations. Dr Sadiq added, "Anand's recovery defied science and at every step challenged his treating team. Anand's unwavering belief in self, motivation and determination became the highlights of his journey in Plexus."

Anand's 11-year long tussle finally ended at Plexus and this end marked the beginning of a new life for him and his family.

About Plexus

At Plexus,we are committed to providing advanced treatment to effectively treat a host of chronic diseases. Our comprehensive services such as stem cell therapy, physiotherapy, occupational therapy, speech & swallowing therapy, cognitive behaviour therapy, customised hand splinting, sensory integration therapy, cognitive rehabilitation therapy to help, treat and rehabilitate patients suffering from neurological and neuropsychiatric disorders. When you choose Plexus, you can expect swift diagnosis, a warm and friendly environment, and thorough treatment all at an affordable price.

Visithttp://www.plexusnc.com/or call+91-8904842087for more details

Media Contact :

Abhishek Saran[emailprotected]+91-9535046900The PRview

Photo: https://mma.prnewswire.com/media/1217269/Plexus_Dr_Naeem_Sadiq.jpg

SOURCE Plexus

Originally posted here:

Paralyzed man walks after 11 years with the help of Plexus Neuro and Stem Cell Research Centre, Bengaluru - PR Newswire India

Global trade impact of the Coronavirus Synthetic Stem Cells Market Report 2020-2026 Research Insights 2020 Global Industry Outlook Shared in Detailed…

Synthetic Stem Cells Market report covers the Introduction, Product Type and Application, Market Overview, Market Analysis by Countries, Market Opportunities, Market Risk and Market Driving Force. Under Coronavirus (COVID19) outbreak globally, this Synthetic Stem Cells industry report provides 360 degrees of analysis from Supply Chain, Import and Export control to regional government policy and future influence on the industry.Focuses on the topmost key Synthetic Stem Cells market manufactures/players like(North Carolina State University, Zhengzhou University), to define, describe and analyze the Sales Volume, Value, Market Share, Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Synthetic Stem Cells Market Competition Landscape, SWOT Analysis and Development Plans in next few years.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Synthetic Stem Cells[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2395700

Which Prime Data Figures are Included in This Synthetic Stem Cells Market Report-Market size (Last few years, current and expected); Market share analysis as per different companies; Synthetic Stem Cells Market forecast; Demand; Price Analysis; Synthetic Stem Cells Market Contributions (Size, Share as per regional boundaries).

Scope of Synthetic Stem Cells Market:Synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Cancers Wounds and Injuries Musculoskeletal Disorders Blood disorders

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Cardiovascular Diseases Neurological Disorders Other Diseases

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2395700

Synthetic Stem Cells Market Regional Analysis Covers:

Some Important Highlights From The Synthetic Stem Cells Market Report Include:

To Get Discount of Synthetic Stem Cells Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2395700

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

Visit link:

Global trade impact of the Coronavirus Synthetic Stem Cells Market Report 2020-2026 Research Insights 2020 Global Industry Outlook Shared in Detailed...

UAE hails success of first bone marrow transplant – The National

The UAE is celebrating the success of its first bone marrow transplant.

Typically used to treat patients with blood and cancer disorders , the landmark procedure was carried out on a patient with multiple myeloma, a form of blood cancer.

Cancer is the third-highest cause of death in the UAE. Patients seeking cell therapy and regenerative medicine often have to travel abroad for treatment.

News of the successful transplant, which was the result of collaboration between Abu Dhabi Stem Cells Centre and Sheikh Khalifa Medical City, represents a major breakthrough for cancer patients living in the UAE who can now seek treatment closer to home to remain with family.

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

Researchers work to develop medication that can be used to treat Covid-19 patients, at Abu Dhabi Stem Cell Centre. Wam Twitter

The doctors and researchers at Abu Dhabi Stem Cell Centre who were involved in the development of a potential Covid-19 treatment. CourtesyAbu Dhabi Stem Cell Centre

The milestone announcement comes as the centre launched the Abu Dhabi Bone Marrow Transplant programme on Monday.

"It fills us with great pride to be part of a first for the country and to make such a life-saving treatment available and accessible to those who need it here," said Dr Fatima Alkaabi, executive Director of the Abu Dhabi Bone Marrow Transplant programme.

"We are very grateful for the support and collaboration of SKMC in making this opportunity possible."

Bone marrow transplants are one of the most established stem cell-based therapies in the treatment of cancer, particularly blood cancers.

The unique procedure developed by the centre involved harvesting peripheral blood stem cells from the patient, who then underwent high-dose chemotherapy to eradicate all cancerous cells and most of the bone marrow.

The harvested stem cells were then infused back into the bloodstream, where they restore the destroyed cells and over the course of two weeks restart the production of healthy non-malignant blood cells.

"The patient is basically without an immune system while waiting for the transfused cells to take effect and must remain in isolation under the strictest infection control guidelines," said Dr Yendry Ventura, general manager of the stem cell centre and Abu Dhabi bone marrow transplant programme director.

"Since we are still in the midst of a global pandemic, we took additional precautions to ensure the best outcome possible for all involved."

Abu Dhabi Stem Cells Centre has been a driving force behind medical research in the country, including playing a key role in the ongoing fight against Covid-19.

Earlier last month, the team announced the results of the trial of its treatment for Covid-19 patients, branded UAECell19.

After opening in December, the centre has already received international press coverage over to its research into a treatment for the virus.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

Updated: July 27, 2020 10:56 PM

Read more:

UAE hails success of first bone marrow transplant - The National

New Combination Therapy for Head and Neck Squamous Cell Carcinoma Shows Potential – Clinical OMICs News

Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat. It is an aggressive life-threatening disease associated with high mortality rates, and accounts for more than 90% of the cancers of the head and neck.

PD1 blockade-based combination therapy has been approved as a first-line treatment for HNSCC. However, the response rate remains relatively low, and patients with HNSCC eventually relapse. Now scientists at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have revealed a potential new combination therapy to treat advanced head and neck squamous cell carcinoma. Using a mouse model, researchers found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences, and eliminated cancer stem cells.

Their findings, BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse, is published inCell Stem Cell.

PD1 blockade combined with chemotherapy has been approved for recurrent or metastatic head and neck cancer. However, response rates remain low and response duration is suggesting that this type of cancer might be resistant to PD1 blockade.

The researchers sought to overcome the resistance and had been studying the role of cancer stem cells and the protein BMI1. BMI1, a polycomb group (PcG) protein, plays a critical role in epigenetic regulation of cell differentiation and proliferation, and cancer stem cell self-renewal.

The researchers used a mouse model of HNSCC that mimicked human cancer development and metastasis, allowing them to perform lineage tracing of BMI1-positive cancer stem cells in an undisturbed tumor immune microenvironment. Then they tested whether BMI1 cancer stem cells could be eliminated by PD1 blockade-based combination therapy using both pharmacological and genetic inhibition of BMI1.

Here, we show that the combination treatment of anti-PD1 and cisplatin enriched BMI1+ CSCs in HNSCC while inhibiting HNSCC growth. In contrast, the pharmacological and genetic inhibition of BMI1 eliminated BMI1+ CSCs and enabled PD1 blockade therapy, resulting in the inhibition of metastatic HNSCC and prevention of HNSCC relapses, the researchers wrote.

BMI1 inhibition induced tumor cell-intrinsic immune responses by recruiting and activating CD8+T cells along with eliminating BMI1 and cancer stem cells.

This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates cancer stem cells by activating antitumor immunity. This discovery holds promise for those with advanced head and neck cancers who are treated with PD1 blockade, but later become resistant to therapy.

More:

New Combination Therapy for Head and Neck Squamous Cell Carcinoma Shows Potential - Clinical OMICs News

The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo – Explica

The treatment was applied to patients suffering from Acute Respiratory Distress Syndrome due to COVID-19. (Photo: . / Edgard Garrido)

The Governor of the State of Hidalgo, Omar Fayad Meneses, announced that through the use of mesenchymal stem cells and exosomes, 26 Hidalguenses who were severe with COVID-19 managed to recover.

This as part of a study carried out by the state government in collaboration with that of Japan, according to the newspaper El Universal. Thirty patients participated in the project, who received an innovative biotechnological therapy to treat COVID-19. They were all in serious condition, but 26 of them managed to recover as a result of the treatment.

The agreement to carry out these activities was agreed on June 13 at a meeting between the Hidalgo administration and the International Association of Cell Therapy for the New Coronavrius (IACT4C).

In presenting the results, the Governor thanked the doctor Tetsuya Fujimori and the researchers, Alex Iryiz and Sergio Alva for having been part of the project.

He assured that based on these promising results, we will seek approval in Hidalgo for this revolutionary treatment for COVID-19. In the same direction, it was reported that an authorization would be requested to make a stem cell processing center that will have a high-level technology called Prometheus.

Mexico has positioned itself in fifth place in Latin America and 13th worldwide. (Photo: . / Edgard Garrido)

Currently, the study is in its second phase, in which it is controlled and analyzes the safety and efficacy of the use of exosomes and human mesenchymal cells intravenously applied.

The Mexican media reported that the treatment was applied to patients who suffered Acute Respiratory Distress Syndrome because of COVID-19.

The president reiterated his willingness to continue collaborating with the Japanese government and that a positive aspect of the crisis is that closer ties between countries so far away are achieved.

The governor also used his Twitter account to report that to date there are 6,467 confirmed cases of COVID-19, in addition to 1,003 deaths. There are also 1,282 recovered cases and 1,282 recovered patients.

These are part of the 44,876 deaths and 402,876 confirmed cases accumulated nationwide until the 58th day of the so-called new normality. Likewise, 449,854 negative cases, 87,538 suspects and 261,457 recovered patients have been counted.

To address the pandemic, the government received on July 28, 20 ventilators for intensive care. The Ministry of Foreign Affairs (SRE) explained that the arrival of the fans was the result of cooperation between the governments of Mexico and the United States and of the conversation between the presidents. Andrs Manuel Lpez Obrador and Donald Trump on April 17, where the acquisition of equipment from that country was agreed.

The Governor thanked Dr. Tetsuya Fujimori and the researchers, Alex Iryiz and Sergio Alva for having been part of the project. (Photo: . / Edgard Garrido)

During the morning conference, the Undersecretary for Prevention and Health Promotion, Hugo Lpez-Gatell, He pointed out that in 20 states the infections of coronavirus increase day by day, however in 12 they go down.

In the mortality ranking, Mexico has positioned itself in fifth place in Latin America and 13th worldwide. About73% of deaths were associated with at least one comorbidity, mainly hypertension, diabetes and obesity.

Actually, Mexico City continues to be the entity with the highest number of active casesfollowed by Guanajuato, Nuevo Len, which rose by one place, Estado de Mxico, Veracruz, which rose by two places, Tabasco, Coahuila, which rose by one site, Jalisco, Yucatan, rose by one place, and Puebla.

MORE ABOUT THIS TOPIC:

Coronavirus in Mexico: the country exceeded 400,000 infections

20 new fans arrived in Mexico from the US

Fatigue, shortness of breath, pain: the 17 symptoms that persist after passing COVID-19

Coronavirus in Mexico: 777 people have taken refuge due to lack of government support

Original post:

The surprising recovery with stem cells of 26 COVID-19 patient in Hidalgo - Explica

Unproven stem cell therapies, and now, strong words from the FDA – BioNews

27 July 2020

There has been general concern around the reports of untested stem celltreatments being sold before they have been proven safe and effective. A recent publication by the US' Food and Drug Administration (FDA)represents an informal forewarning to the rogue doctors operating outside of the regulatory regime that they may not get extra time to comply with the agency's strict regulation of regenerative medicine products.

This piece, which uses strong language, underscores the regulatory agency's firm commitment to evidence-based regenerative products.

In 2017, the FDA articulated the regulatory criteria for product marketing through the publication of four guidance documents. These documents build upon the agency's existing risk-based, flexible regulatory regime. They enable stakeholders to understand better how the regulatory criteria apply to their products by clarifying complex technical definitions such as 'minimal manipulation' and 'homologous use'.

This coming November will mark the end of the three years of enforcement discretion announced by the FDA when it first set up this stringent regulatory framework. This approach allows product manufacturers sufficient time to engage with the agency to comply with the requirements, eg, to determine whether they must submit a marketing authorisation application to the FDA for their approval. In the recent piece, there is no indication of a deadline extension.

The authors, Dr Stephen Hahn (FDA's new commissioner) and Dr Peter Marks (Centre for Biologics and Evaluation and Research (CBER) director), state that '... these products, whether autologous (taken from the patient) or allogeneic (donated), are not inherently safe and may be associated with serious adverse consequences'. This piece places the unproven stem cell therapy issue in the context of the COVID-19 pandemic, during which some clinics selling unproven stem cell therapies have exploited the fears of the vulnerable public.

It also indicates that 'the increasing number of adverse events being reported following the widespread use of unapproved regenerative medicine therapies at hundreds of clinics across the country make it necessary for the FDA to act to prevent harm to individuals receiving them.' This point is indeed commendable as it represents the increasingly proactive measures being taken by the FDA in taking enforcement action.

The authors request engagement from patients, their family and friends as well as clinicians 'to help to ensure that instead of remaining unintentionally or intentionally hidden, potentially harmful unapproved regenerative medicine therapies are identified and then removed from the market.' Some clinics may attempt to avoid being on the FDA's radar, however, there is reliable research that should help inform the FDA about the emergence of hundreds, if not a thousand such centres in the US.

Crucially, the article provides some useful and practical guidelines for patients to refer to when evaluating whether a cellular product is offered in compliance with the FDA regulations. For patients contemplating therapies involving a cellular product, the authors recommend the following steps as appropriate practices: first, they need to verify whether the product is FDA-approved or whether an investigational new drug (IND) application for the product is currently on file with the FDA. Next, the patient must provide written informed consent to participate in a clinical trial under that IND and compliance with institutional review board (IRB) requirements.

Moreover, the patient must not be charged for either the unapproved product or for participation in the clinical trial unless there is evidence of benefit to the patient, in which case the amount charged must not exceed the actual direct costs to create the product (cost recovery). And this must be documented by a certified public accountant.

On a critical note, patients (and family, friends and clinicians) are encouraged to report adverse medical events after receiving the product and the health care provider must clearly explain the specific steps for doing so, such as filling in patient-friendly forms to report the matter. Such reports will enable the FDA to get a complete picture of the range of dubious activities.

Finally, patients enrolled in the clinical trial should receive a summary of results after the clinical trial. Transparency, it is felt, will engender trust.

Interestingly, the authors state that medical professionals, including primary care physicians and nurses, are in the best position to assist patients in identifying whether the particular regenerative medicine treatment is appropriate for them to pursue. It is doubtful whether this represents an accurate position as there may be a wide range of knowledge and awareness of stem cell interventions even among the doctors.

The article, written amid a pandemic when the FDA is occupied with other pressing matters, reiterates the agency's obligation to its fundamental mission. Collectively, this piece and the recent escalation in warnings, as well as untitled letters sent by FDA to clinics proffering unapproved stem cell treatments, may indicate that these companies may not be granted more time to comply with the requirements. The remaining months may provide some inkling into what the enforcement situation is likely to be as the FDA's enforcement discretion period finishes in November 2020.

More:

Unproven stem cell therapies, and now, strong words from the FDA - BioNews

R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico – PR Web

Stem Cell and Exosome Therapy for Autism in Mexico (888) 988-0515

SCOTTSDALE, Ariz. (PRWEB) July 23, 2020

R3 International is now including exosomes with its stem cell therapy program in Mexico for autism. They have been shown to be an effective, safe option for autism patients.

Stem cell and exosome therapy for autism has shown excellent outcomes at R3 International in Tijuana, with the procedures performed by licensed, expert doctors. The doses of biologic are calculated based on the patient's weight. Up to 200 million stem cells are included, along with over 100 billion exosomes.

Autism treatment with regenerative biologics has been very safe and each patient (and family) receives an escort from San Diego to the treatment clinic in Mexico. The autism stem cell treatment center is only twenty minutes from the San Diego International Airport.

According to R3 CEO David Greene, MD, MBA, "Our autism program includes first rate biologics with cell counts that are very high. Safety is paramount, and the lab's safety standards exceed those of the FDA. We set the program up to be extremely cost effective with several options to make it convenient for patient families!"

There are multiple treatment options for autism patients including:1. A one time visit with 30 or 50 million stem cells starting at $2975.2. A 5 day stay with several treatments starting at $8975.3. Several visits over a year period, all inclusive starting at $10,475.

The exosome part of the therapy includes billions of exosomes and is provided at no additional charge. Exosomes are derived from mesenchymal stem cells, and are amazing at cell to cell communication. Research has shown that exosomes are vital in the development of neural circuits, which can enhance the clinical outcomes for autism (Natl Acad Sci, 2019).

To get started with stem cell and exosome therapy for autism in Mexico, call R3 today at (888) 988-0515.

Share article on social media or email:

See original here:

R3 International Now Including Exosomes with Stem Cell Therapy Program for Autism in Mexico - PR Web

R3 International Offering New Stem Cell Therapy for Neuropathy Program in Mexico – Benzinga

SCOTTSDALE, Ariz., July 23, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new stem cell therapy for neuropathy program in Mexico. The regenerative treatments involve up to 200 million stem cells and have been very effective at relieving neuropathic pain.

Peripheral neuropathy affects many millions of Individuals worldwide, and often leads to chronic, debilitating pain. It may occur as a result of diabetes, alcoholism, radiation, chemo or many other potential causes.

Stem cell and exosome therapy for neuropathy has achieved tremendous results at R3 International. Stem cells and exosomes are excellent at promoting nerve regeneration and new blood vessel formation.

According to R3 CEO David Greene, MD, MBA, "Patients lament the traditional pain medications they are offered for relief, which may lead to addiction or an overdose. The stem cell and exosome therapy offered at R3 International is safe and very effective for relief and helping patients be able to walk farther."

Treatments at the clinic are outpatient, and involve anywhere from 30 million stem cells up to 200 million. The treatment starts at only $2975, with escorted transportation included from San Diego to the clinic and back. The patient concierge representative goes with the patient to the treatment as well.

The process starts with a free phone consultation with the R3 licensed, experienced stem cell doctor. Once treatment is scheduled, the R3 patient concierge assists with travel logistics.

In addition to the neuropathy stem cell program, R3 International also provides stem cell treatment in Mexico for COPD, kidney failure, autism, arthritis, diabetes, hepatitis, Lyme disease, MS, ALS, Alzheimers and more.

Call (888) 988-0515 to schedule the free phone consultation.

SOURCE R3 Stem Cell International

See the article here:

R3 International Offering New Stem Cell Therapy for Neuropathy Program in Mexico - Benzinga

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health – Yahoo Finance

Boehringer Ingelheim, a market leader in animal health, has acquired Global Stem cell Technology (GST), a Belgian veterinary biotech company. GST is dedicated to the research, development and production of evidence-based, regenerative medicines (stem cell therapies) used to treat orthopedic and metabolic diseases in animals. Boehringer Ingelheim already entered into a partnership with GST in 2018; in 2019, the companies launched Arti-Cell Forte in Europe.

Arti-Cell Forte is testimony to the innovation strength that lies within both companies. It is the first-ever stem cell product in the veterinary world granted marketing authorization by the European Commission. The acquisition and integration of GST will accelerate the development pipeline of Boehringer Ingelheim while maintaining its focus on setting new standards of care for animals.

"Collaboration with external partners plays an essential role in helping us expand our portfolio. After two years of a very successful partnership, we have decided to acquire GST. We are convinced that its expertise in the field of state-of-the art stem cell products will help us bring even more innovative solutions to our customers," shares Jean-Luc Michel, Head of Global Strategic Marketing, Boehringer Ingelheim Animal Health.

"Boehringer Ingelheim wants to lead a new wave of innovation in the veterinary field. This ambition is a natural fit with GSTs management, staff and vision. From the very beginning we aimed to change the veterinary field, a role we will continue to play as a new R&D division within Boehringer Ingelheim," says Jan Spaas, CEO of GST.

"This decision is fully aligned with our recently refocused strategic direction. Stem cell research areas and regenerative medicine offer an exciting potential for the next wave of innovation we are actively pursuing. In addition, strengthening external partnerships to accelerate our innovative efforts and growth is one of the key elements of our strategy," adds Eric Haaksma, Head of Global Innovation at Boehringer Ingelheim Animal Health.

The companies did not disclose the financial terms of the deal.

For references and notes to editors, please visit:

http://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-global-stem-cell-technology

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200727005234/en/

Contacts

Boehringer IngelheimAnimal Health Communication Tereza Urbankova 552 16 Ingelheim, GermanyPhone: +49 6132 77 184817Email: press@boehringer-ingelheim.com

Visit link:

Boehringer Ingelheim acquires GST to strengthen its stem cell capabilities in Animal Health - Yahoo Finance

A once-in-6,800-years wedding proposal: CNY couple gets engaged under Comet Neowise – syracuse.com

A worldwide health event and a canceled vacation couldnt stop John Nicotera, of Utica, from pulling off an astronomical wedding proposal under Comet Neowise for his girlfriend.

Nicotera and now-fianc Erica Pendrak met on Instagram. They both live in Utica and are teachers in the Central NY area.

We knew of each other. We both coach in the area and have some mutual friends. She posted something one day about basketball and I made a comment underneath it and the conversation kept going from there, he said.

For Christmas in 2019, he gave Pendrak a trip to Oregon in July 2020. He had a tentative plan to propose to her at Crater Lake National Park while they were there. The trip was canceled due to the coronavirus pandemic in May and Nicotera began to think about what his plan B would be for the engagement.

I was bummed that it was canceled. Any plan I came up just didnt seem to compare to Crater Lake, he said.

Nicotera calls himself a space junkie, always following news about space events, watching SpaceX launches, and reading books about space. When Comet Neowise was set to arrive and be visible from Upstate NY, he asked Pendrak if she would view it with him. After she agreed view the rare comet, the idea to propose to her under the celestial event clicked.

Now he had to set plans in motion to make it happen, but he quickly realized he might only have one chance for it all to work.

We had other things going on during the week and that was really the only night that worked for us. At that point I knew I needed the clouds to be away, the skies to be clear, and mother nature to be friendly to me, he said.

Not only were busy schedules an issue, but according to NASA, the Neowise comet only comes around every 6,800 years.

Nicotera had originally enlisted the help of photographer friend Tim Leach of Old Forge, NY, to get ideas of the perfect spot to see the comet. When Nicotera forgot to bring his binoculars, he reached out to Leach to see if he could borrow a pair. Leach offered to take photos with them and let them see the comet through the camera. Thats when the proposal idea came tumbling out.

I spilled the beans to him and I told him about the idea to get a photo of the proposal with the comet, Nicotera said.

To make sure everything worked perfectly, he said said it was a stressful day, but Pendrak said she was none the wiser about the master plan.

We had just wanted to get away for the day and enjoy the boat and see the comet at night. His friend Tim offered to take couples pictures so I was excited about that and said yeah lets definitely get some pictures, she said.

Leach and his girlfriend met up with the CNY couple near McCauley Mountain and got ready to view the comet. Leachs main camera was set up for a timelapse which he said is best for astrophotography and he had a small point-and-shoot camera ready to go for the moment of the proposal.

John Nicotera and Erica Pendrak as the sun sets in the Adirondacks. Nicotera surprised Pendrak that night by asking her to marry him under Comet Neowise.

When Nicotera popped the question, Leach was ready to take the shot, but capturing them and the comet with very little light required them to stand still for seven seconds per photo. After he got down on one knee, Pendrak waited seven seconds for Nicotera to ask her to marry him.

I just found the best middle ground in the time I had to shoot the photo. John and Erica had to be still for about seven seconds. You will notice that the photo is slightly out of focus, mostly due to the fact that it is nearly impossible for a person to be perfectly still for seven seconds, Leach said. But, it is the moment that counts.

John Nicotera and Erica Pendrak of Utica, NY got engaged under Comet Neowise near McCauley Mountain in the Adirondacks. The photo was captured by Leach Photography.@tleach18 | Provided photo

The result was out-of-this-world photos that have been shared across the internet after Nicotera posted them on Twitter. The couple has been featured on Good Morning America, CNN, ABC News, The Weather Channel, Fox News, and more.

Its crazy. It was a shock when we woke up the next morning and we saw how many likes and retweets this got. Its awesome that we have that moment that we can keep and cherish and have, but that its being shared is awesome, Pendrak said.

The couple has not set a date yet, but is shooting for summer 2021.

Right now were just enjoying everything, Pendrak said.

READ MORE

High Peaks elopement: Hiking couple get married on Adirondack mountain summit

Picnic in Upstate NY: 30 scenic places to eat outdoors

Expert: 5 tips on hiking Adirondack or Catskill peaks in sunny, abusively hot weather

40 highest-rated wedding venues in Upstate New Yorks biggest cities

Link:

A once-in-6,800-years wedding proposal: CNY couple gets engaged under Comet Neowise - syracuse.com

Spellbinding image captures rare comet, northern lights, Milky Way, and bioluminescence in B.C. (PHOTOS) – Vancouver Is Awesome

While a number of breathtaking imageshave surfaced of therare comet NEOWISE in B.C. skies, a local photographer captured a truly awe-inspiringmoment onVancouver Island.

The NEOWISEcomet, discovered in March by NASAs Neowise infrared space telescope, reached its closest point to the sun on July 3, which caused the frozen ice ball to heat up and burn gas and dust off its surface.

NASAexplains that, "This very close passage by the Sun is cooking the comet's outermost layers, causing gas and dust to erupt off the icy surface and creating a large tail of debris. And yet the comet has managed to survive this intense roasting."

Just before the weekend, locals were able toview of the astral displayjust below the BigDipper when it reachedits closest proximityto earth, as it madeits celestial journey through the heavens above.

"What a night! With the potential for some aurora action andNeowise fading day by day, I decided to head up here last night," writes McColm on Twitter.

"The comet, bioluminescence, the Milky Way and even a bit of aurora - just wow."

McColum has also shared a number of other mesmerizing photos of NEOWISEon Twitter over the past weeks.

You canview more of McColum's photograhy on his website HERE.

Last week, a local astrophotographershareda remarkable image of a rare comet andAurora Borealis at Harrison Lake.

Liron Gertsman, a 19-year-oldastrophotographer and astronomy enthusiast, tellsVancouver Is Awesomein an email that he's never had the opportunity to shoot a comet before. The last comet visible from the northern hemisphere that was comparable to NEOWISE was Comet HaleBopp in 1997, which wasbefore hewas born.

The previous night, Gerstman also photographed the comet from over English Bay, resulting in a very "Vancouver" landscape image featuring the comet. Read more and see the photosHERE.

Go here to see the original:

Spellbinding image captures rare comet, northern lights, Milky Way, and bioluminescence in B.C. (PHOTOS) - Vancouver Is Awesome


...678910...203040...